Updated New Zealand cardiovascular disease risk-benefit prediction guide

BMJ

Volumn 320, Issue 7236, 2000, Pages 709-

  Jackson, Rodney ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SHORT SURVEY;

CARDIOVASCULAR DISEASES; HUMANS; NEW ZEALAND; RISK ASSESSMENT; RISK FACTORS;

EID: 0034635906     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.320.7236.709     Document Type: Article

References (7)

1. MacMahon S Rogers A. The effects of antihypertensive treatment on vascular disease: re-appraisal of the evidence in 1993. J Vasc Med Biol 1993; 4: 265–271.
2. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339–1342.
3. National Health Committee. Guidelines for the management of mildly raised blood pressure in New Zealand. Wellington: Ministry of Health, 1995.
4. Dyslipidaemia Advisory Group. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224–232.
5. Anderson KV Odell PM Wilson PWF Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–298.
6. Mulrow CD Cornell JA Herrera CR Kadri A Farnett L Aguilar C. Hypertension in the elderly. Implications and generalizability of randomised trials. JAMA 1994; 272: 1932–1938.
7. LaRosa JC He J Vupputuri S. Effect of statins on risk of coronary disease. Meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.